Drug-interaction safety
Clarithromycin and colchicine: spacing does not solve this interaction
An interaction caused by increased exposure is not fixed by moving tablets a few hours apart. The clarithromycin label describes serious colchicine toxicity and a contraindication when renal or hepatic impairment is present. Read the organ-function context before proposing a workaround.
Sources checked October 8, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Identify both the pair and the patient
The cited clarithromycin tablet label contraindicates coadministration with colchicine in renal or hepatic impairment. It also reports life-threatening and fatal colchicine toxicity with the interaction. A computer alert that omits organ function is only the beginning of the review.
Recover the actual medicines, doses, last administrations and kidney and liver context. Colchicine may be used intermittently for a flare and missing from the regular list. Do not assume a patient has stopped it because the prescription was not issued this month.
Distinguish metabolic interaction from a gut-binding problem
Clarithromycin inhibits pathways relevant to colchicine exposure, including CYP3A4 and P-glycoprotein. That differs from a cation binding an antibiotic in the gut. Moving one tablet to breakfast and the other to bedtime does not remove this mechanism.
The full label describes dose adjustment and monitoring considerations for some patients without renal or hepatic impairment. Those conditional pathways do not cancel the contraindication in the impaired group. Do not quote an adjustment rule from one branch as permission for another.
Escalate symptoms without waiting for a calculation
New gastrointestinal symptoms, weakness or other concerning findings with the combination need assessment for toxicity and other causes. A dose that looked normal before the interacting antibiotic was added may no longer represent the same exposure.
Do not diagnose colchicine toxicity solely from diarrhea, but do not dismiss symptoms as a routine antibiotic effect without reviewing the pair. Preserve timing and exposures for the treating team and seek the urgency appropriate to the actual symptoms.
Review the rest of the list
The clarithromycin label also contraindicates concomitant lovastatin and simvastatin because of myopathy and rhabdomyolysis risk. Other interacting medicines and cardiac-risk context matter. Resolving colchicine alone does not complete the prescription safety review.
An alternative antibiotic must still fit the infection and patient. This exercise teaches why the pair is a stop-and-review problem, not which replacement to prescribe. Do not silently omit a chronic drug or substitute an antibiotic without a source-grounded clinical plan.
A worked case
A patient with renal impairment uses colchicine for gout and receives clarithromycin. A proposed fix is to take colchicine in the morning and clarithromycin at night. What is wrong?
- Identify the contraindicated pair in the renal-impairment branch.
- Recognize that time separation does not remove the metabolic/transport interaction.
- Contact the treating team for a clinically suitable plan and review other interactions and any symptoms.
Answer: The timing workaround does not resolve the contraindication; the treatment plan needs review.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Can a few hours of separation make this pair safe in renal impairment?
No. The cited contraindication remains.
2. Does a colchicine adjustment pathway in another population override this branch?
No. Population-specific conditions must be preserved.
3. Should the pharmacist choose any noninteracting antibiotic without checking the infection?
No. The alternative must still be appropriate for the clinical indication.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.